Background: Health inequities among people with HIV may be compounded by disparities in the prevalence of comorbidities associated with an increased risk of severe illness from COVID-19. Setting: Complex sample survey designed to produce nationally representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the United States. Methods: We estimated the prevalence of having ≥1 diagnosed comorbidity associated with severe illness from COVID-19 and prevalence differences (PDs) by race/ethnicity, income level, and type of health insurance. We considered PDs ≥5 percentage points to be meaningful from a public health perspective. Results: An estimated 37.9% [95% confidence interval (CI): 36.6 to 39.2] of adults receiving HIV care had ≥1 diagnosed comorbidity associated with severe illness from COVID-19. Compared with non-Hispanic Whites, non-Hispanic Blacks or African Americans were more likely [adjusted PD, 7.8 percentage points (95% CI: 5.7 to 10.0)] and non-Hispanic Asians were less likely [adjusted PD, −13.7 percentage points (95% CI: −22.3 to −5.0)] to have ≥1 diagnosed comorbidity after adjusting for age differences. There were no meaningful differences between non-Hispanic Whites and adults in other racial/ethnic groups. Those with low income were more likely to have ≥1 diagnosed comorbidity [PD, 7.3 percentage points (95% CI: 5.1 to 9.4)]. Conclusions: Among adults receiving HIV care, non-Hispanic Blacks and those with low income were more likely to have ≥1 diagnosed comorbidity associated with severe COVID-19. Building health equity among people with HIV during the COVID-19 pandemic may require reducing the impact of comorbidities in heavily affected communities.
19 August 2026 in Journal of the Association of Nurses in AIDS Care
We present nationally representative estimates of cancer diagnoses among US persons with HIV (PWH) using data from the Medical Monitoring Project, a complex sample survey of US adults with diagnosed HIV. Data were collected June 2019–May 2023 from a probability sample of 14,798 PWH. Weighted frequencies and percentages of cancer diagnoses during the past 24 months were calculated, and differences between the groups were quantified using prevalence ratios. An estimated 66,641 PWH (6.7%) had a cancer diagnosis and 54,863 (5.5%) had a non–AIDS-defining cancer diagnosis. PWH with a cancer diagnosis had higher prevalence of formerly smoking cigarettes, being unable to work or retired, poor self-rated health, advanced HIV disease, retention in HIV care, and viral suppression compared with those without a cancer diagnosis. Providing recommended cancer screenings and cancer prevention and treatment strategies—in addition to HIV standard of care—may support overall well-being among PWH.
4 September 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Background: Long-acting injectable antiretroviral therapy (LA-ART) has enormous potential benefit for increasing viral suppression among persons with HIV (PWH). Setting: U.S. HIV care facilities. Methods: We analyzed data on past 12-month LA-ART prescriptions collected over 3 annual data collection cycles (2021–2023) from probability samples of U.S. adults with HIV (collected 6/1/2021–5/30/2024, N=11,524). We report weighted percentages of PWH prescribed LA-ART and use prevalence ratios (PRs) with predicted marginal means and 95% confidence intervals (CIs) to quantify differences in prescription of LA-ART over time and between groups. Results: The percentage of PWH prescribed LA-ART increased from 0.4% (CI 0.2–0.7) in the 2021 cycle to 3.4% (CI 2.8–3.9) in the 2023 cycle (PR 7.8 [CI 4.5–13.6]). During the 2022-2023 cycles, prescription of LA-ART was higher among those living in Northeastern Medical Monitoring Project (MMP) states versus Southern MMP states (3.4% [CI 2.4–4.3] vs. 1.9% [CI 1.3–2.5], PR 1.8 [1.2–2.8]) and those receiving care at Ryan White HIV/AIDS program (RWHAP)-funded versus non-funded facilities (2.9% [CI 2.4–3.4] vs. 1.8% [CI 1.3–2.4], PR 1.6 [CI 1.1–2.2]). Older age (>50 vs. <40 years) was also associated with lower ART prescription. Conclusion: Prescription of LA-ART is increasing among U.S. adults with HIV, though prevalence remains low. LA-ART uptake lagged in the South, where HIV infections and negative health outcomes are disproportionately high. Comprehensive HIV care delivery—such as found in RWHAP-facilities—may facilitate LA-ART adoption.